Cargando…

Sertraline-Induced Optic Nerve Dysfunction

This case report describes a rare case of Sertraline-induced optic nerve dysfunction with optic disc edema (papilledema) in both eyes in a 32-year-old male who was on chronic sertraline therapy for the treatment of generalized anxiety disorder and three panic episodes. The patient was presented to o...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuallut, Ismail, Alqassim, Ahmad Y, Ayyashi, Rubuah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151102/
https://www.ncbi.nlm.nih.gov/pubmed/37139272
http://dx.doi.org/10.7759/cureus.36976
_version_ 1785035467539873792
author Abuallut, Ismail
Alqassim, Ahmad Y
Ayyashi, Rubuah
author_facet Abuallut, Ismail
Alqassim, Ahmad Y
Ayyashi, Rubuah
author_sort Abuallut, Ismail
collection PubMed
description This case report describes a rare case of Sertraline-induced optic nerve dysfunction with optic disc edema (papilledema) in both eyes in a 32-year-old male who was on chronic sertraline therapy for the treatment of generalized anxiety disorder and three panic episodes. The patient was presented to our ophthalmology clinic with two bubbles with dark borders in both eyes on the far side for a few months. An optical coherence tomography showed that retinal nerve fiber layer thickness was 98 microns in OD (right eye) and 105 microns in OS (left eye). Another optical coherence tomography findings in both eyes were the elevation of superior and inferior quadrants. Optical coherence tomography findings supported the diagnosis of optic disc edema (papilledema) in both eyes. Magnetic resonance imaging of the brain revealed symmetrical enlargement in the optic nerves (8 mm in diameter at its thickest point). However, abnormal enhancement was absent, excluding optic neuritis. Sertraline was discontinued and replaced by fluoxetine 20 mg. Five months later, papilledema was resolved. On follow-up one month later, the patient continued to improve in terms of symptoms and test results. The case presented demonstrates a rare association between sertraline use and optic nerve dysfunction. Adding to the increasing number of patients using sertraline worldwide, further research is warranted to investigate the incidence of this association and explore possible pathologic mechanisms.
format Online
Article
Text
id pubmed-10151102
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101511022023-05-02 Sertraline-Induced Optic Nerve Dysfunction Abuallut, Ismail Alqassim, Ahmad Y Ayyashi, Rubuah Cureus Ophthalmology This case report describes a rare case of Sertraline-induced optic nerve dysfunction with optic disc edema (papilledema) in both eyes in a 32-year-old male who was on chronic sertraline therapy for the treatment of generalized anxiety disorder and three panic episodes. The patient was presented to our ophthalmology clinic with two bubbles with dark borders in both eyes on the far side for a few months. An optical coherence tomography showed that retinal nerve fiber layer thickness was 98 microns in OD (right eye) and 105 microns in OS (left eye). Another optical coherence tomography findings in both eyes were the elevation of superior and inferior quadrants. Optical coherence tomography findings supported the diagnosis of optic disc edema (papilledema) in both eyes. Magnetic resonance imaging of the brain revealed symmetrical enlargement in the optic nerves (8 mm in diameter at its thickest point). However, abnormal enhancement was absent, excluding optic neuritis. Sertraline was discontinued and replaced by fluoxetine 20 mg. Five months later, papilledema was resolved. On follow-up one month later, the patient continued to improve in terms of symptoms and test results. The case presented demonstrates a rare association between sertraline use and optic nerve dysfunction. Adding to the increasing number of patients using sertraline worldwide, further research is warranted to investigate the incidence of this association and explore possible pathologic mechanisms. Cureus 2023-03-31 /pmc/articles/PMC10151102/ /pubmed/37139272 http://dx.doi.org/10.7759/cureus.36976 Text en Copyright © 2023, Abuallut et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Ophthalmology
Abuallut, Ismail
Alqassim, Ahmad Y
Ayyashi, Rubuah
Sertraline-Induced Optic Nerve Dysfunction
title Sertraline-Induced Optic Nerve Dysfunction
title_full Sertraline-Induced Optic Nerve Dysfunction
title_fullStr Sertraline-Induced Optic Nerve Dysfunction
title_full_unstemmed Sertraline-Induced Optic Nerve Dysfunction
title_short Sertraline-Induced Optic Nerve Dysfunction
title_sort sertraline-induced optic nerve dysfunction
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151102/
https://www.ncbi.nlm.nih.gov/pubmed/37139272
http://dx.doi.org/10.7759/cureus.36976
work_keys_str_mv AT abuallutismail sertralineinducedopticnervedysfunction
AT alqassimahmady sertralineinducedopticnervedysfunction
AT ayyashirubuah sertralineinducedopticnervedysfunction